Chapter 32 : Echinocandins in the Treatment of Aspergillosis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in

Echinocandins in the Treatment of Aspergillosis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap32-1.gif /docserver/preview/fulltext/10.1128/9781555815523/9781555814380_Chap32-2.gif


In the presence of caspofungin, blunting and abnormal branching of the hyphae in actively growing areas of the cell are observed, primarily at the tips and branching points. These observations are consistent with the mechanism of action but do not fit the classical definitions of a fungicidal or fungistatic agent. Echinocandins are large molecules with a relative molecular weight of approximately 1,200. Due to their large molecule size and poor oral bioavailability (less than 10%), echinocandins are available for parenteral administration only. Recently, the European Organization for Research and Treatment of Cancer reported on their multicenter clinical trial that evaluated caspofungin as first-line treatment for proven and probable invasive aspergillosis in 61 evaluable patients with hematological cancer. Four compassionate use studies conducted prior to licensure in several different countries showed that caspofungin produced favorable responses in a variety of patients with invasive aspergillosis, most of whom demonstrated refractoriness to or intolerance of prior systemic antifungal therapy. Initial reports of combination therapy in invasive aspergillosis have focused on refractory disease. Echinocandins are generally very well tolerated both in the healthy subjects of the clinical pharmacology studies and in patients with a wide spectrum of diseases and receiving many concomitant medications who were included in the clinical trials. In clinical studies of patients with invasive aspergillosis, caspofungin and micafungin are well-tolerated for prolonged treatment durations (up to 162 days for caspofungin), and the favorable safety profile was maintained with extended therapy.

Citation: Maertens J, Maertens V. 2009. Echinocandins in the Treatment of Aspergillosis, p 435-443. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch32

Key Concept Ranking

Fungal Infections
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Abruzzo, G. K.,, A. M. Flattery,, C. J. Gill,, L. Kong,, J. G. Smith,, V. B. Pikounis,, J. M. Balkovec,, A. F. Bouffard,, J. F. Dropinski,, H. Rosen,, H. Kropp, and, K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41: 23332338.
2. Abruzzo, G. K.,, C. J. Gill,, A. M. Flattery,, L. Kong,, C. Leighton,, J. G. Smith,, V. B. Pikounis,, K. Bartizal, and, H. Rosen. 2000. Efficacy of echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. 44:23102318.
3. Aliff, T. B.,, P. G. Maslak,, J. G. Jurcic,, M. L. Heaney,, K. N. Cathcart,, K. A. Sepkowitz, and, M. A. Weiss. 2003. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97: 10251032.
4. Bates, D. W.,, L. Su,, D. T. Yu,, G. M. Chertow,, D. L. Seger,, D. R. Gomes,, E. J. Dasbach, and, R. Platt. 2001. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32: 686693.
5. Bowman, J. C.,, G. K. Abruzzo,, J. W. Anderson,, A. M. Flattery,, C. J. Gill,, V. B. Pikounis,, D. M. Schmatz,, P. A. Liberator, and, C. M. Douglas. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:34743481.
6. Bowman, J. C.,, P. S. Hicks,, M. B. Kurtz,, H. Rosen,, D. M. Schmatz,, P. A. Liberator, and, C. M. Douglas. 2002. The antifungal echino-candin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:30013012.
7. Cagnoni, P. J.,, T. J. Walsh,, M. M. Prendergast,, D. Bodensteiner,, S. Hiemenz,, R. N. Greenberg,, C. A. Arndt,, M. Schuster,, N. Seibel,, V. Yeldandi, and, T. B. Tong. 2000. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently neutropenic patients. J. Clin. Oncol. 18: 24762483.
8. Caillot, D.,, A. Thiébaut,, R. Herbrecht,, S. de Botton,, A. Pigneux,, F. Bernard,, J. Larché,, F. Monchecourt,, S. Alfandari, and, L. Mahi. 2007. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110: 27402746.
9. Candoni, A.,, R. Mestroni,, D. Damiani,, M. Tiribelli,, A. Michelutti,, F. Silvestri,, M. Castelli,, P. Viale, and, R. Fanin. 2005. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur. J. Haematol. 75: 227233.
10. Chandrasekar, P. H., and, J. D. Sobel. 2006. Micafungin: a new echin-ocandin. Clin. Infect. Dis. 42: 11711178.
11. Debono, M.,, B. J. Abbott,, J. R. Turner,, L. C. Howard,, R. S. Gordee,, A. S. Hunt,, M. Barnhart,, R. M. Molloy,, K. E. Willard, and, D. Fukuda. 1988. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann. N. Y. Acad. Sci. 544: 152167.
12. Debono, M., and, R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Ann. Rev. Microbiol. 48: 471497.
13. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362: 11421151.
14. Denning, D. W.,, K. A. Marr,, W. M. Lau,, D. P. Facklam,, V. Ratan-atharathorn,, C. Becker,, A. J. Ullmann,, N. L. Seibel,, P. M. Flynn,, J. A. van Burik,, D. N. Buell, and, T. F. Patterson. 2006. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 53: 337349.
15. Eiden, C.,, H. Peyri’ere,, M. Cociglio,, S. Djezzar,, S. Hansel,, J. P. Blayac,, D. Hillaire-Buys, and Network of the French Pharmacovigilance Database. 2007. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann. Pharmacother. 41:755763.
16. Frothingham, R. 2002. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin. Infect. Dis. 35: 896897.
17. Glasmacher, A.,, O. A. Cornely,, K. Orlopp,, S. Reuter,, S. Blaschke,, M. Eichel,, G. Silling,, B. Simons,, G. Egerer,, M. Siemann,, M. Florek,, R. Schnitzler,, P. Ebeling,, J. Ritter,, H. Reinel,, P. Schütt,, H. Fischer,, C. Hahn, and, G. Just-Nuebling. 2006. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J. Antimicrob. Chemother. 57:127134.
18. Hector, R. F. 1993. Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. 6: 121.
19. Herbrecht, R.,, D. W. Denning,, T. F. Patterson,, J. E. Bennett,, R. E. Greene,, J. W. Oestmann,, W. V. Kern,, K. A. Marr,, P. Ribaud,, O. Lortholary,, R. Sylvester,, R. H. Rubin,, J. R. Wingard,, P. Stark,, C. Durand,, D. Caillot,, E. Thiel,, P. H. Chandrasekar,, M. R. Hodges,, H. T. Schlamm,, P. F. Troke,, B. de Pauw, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347: 408415.
20. Herbrecht, R.,, D. Graham,, M. Schuster,, T. Henkel,, D. Krause,, J. Schranz,, J. Garbino,, D. Caillot,, J. Reinhardt, and, J. Maertens. 2004. Safety and tolerability of combination anidulafungin and li-posomal amphotericin B for the treatment of invasive aspergillosis. Biol. Blood Marrow Transplant. 10:91.
21. Hope, W. W.,, T. J. Walsh, and, D. W. Denning. 2005. Laboratory diagnosis of invasive aspergillosis. Lancet Infect. Dis. 5:609622.
22. Imhof, A.,, D. J. Schaer,, U. Schanz, and, U. Schwarz. 2006. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med. Wkly. 136:739742.
23. Kartsonis, N. A.,, A. J. Saah,, L. C. Joy,, A. F. Taylor, and, C. A. Sable. 2005. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect. 50: 196205.
24. Kinoshita, K.,, H. Iwasaki,, H. Uzui, and, T. Ueda. 2006. Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells. Transl. Res. 148: 207213.
25. Kontoyiannis, D. P.,, R. Hachem,, R. E. Lewis,, G. A. Rivero,, H. A. Torres,, J. Thornby,, R. Champlin,, H. Kantarjian,, G. P. Bodey, and, I. Raad. 2003. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292299.
26. Kulemann, V.,, M. Bauer,, W. Graninger, and, C. Joukhadar. 2005. Safety and potential of drug interactions of caspofungin and vori-conazole in multimorbid patients. Pharmacology 75:165178.
27. Kurtz, M. B., and, J. H. Rex. 2001. Glucan synthase inhibitors as antifungal agents. Adv. Protein Chem. 56:423475.
28. Maertens, J., and, M. Boogaerts. 2000. Fungal cell wall inhibitors. Curr. Pharm. Des. 6:225239.
29. Maertens, J.,, K. Theunissen, and, M. Boogaerts. 2002. Invasive aspergillosis: focus on new approaches and new therapeutic agents. Curr. Med. Chem. Anti Infect. Agents 1:6581.
30. Maertens, J.,, I. Raad,, G. Petrikkos,, M. Boogaerts,, D. Selleslag,, F. B. Petersen,, C. A. Sable,, N. A. Kartsonis,, A. Ngai,, A. Taylor,, T. F. Patterson,, D. W. Denning,, T. J. Walsh, et al. 2004. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39: 15631571.
31. Maertens, J.,, A. Glasmacher,, R. Herbrecht,, A. Thiebaut,, C. Cordon-nier,, B. H. Segal,, J. Killar,, A. Taylor,, N. Kartsonis,, T. F. Patterson,, M. Aoun,, D. Caillot,, C. Sable, et al. 2006. Multicenter, noncom-parative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107: 28882897.
32. Marr, K. A.,, R. A. Carter,, F. Crippa,, A. Wald, and, L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34: 909917.
33. Marr, K. A.,, R. Hachem,, G. Papanicolaou,, J. Somani,, J. M. Arduino,, C. J. Lipka,, A. L. Ngai,, N. Kartsonis,, J. Chodakewitz, and, C. Sable. 2004a. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transplant. Infect. Dis. 6: 110116.
34. Marr, K. A.,, M. Boeckh,, R. A. Carter,, H. W. Kim, and, L. Corey. 2004b. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39: 797802.
35. Marr, K. A.,, M. Boeckh, and, H. W. Kim. 2005. Combination anti-fungal therapy for invasive aspergillosis. Clin. Infect. Dis. 40: 10751076. (Author reply.)
36. Meersseman, W.,, K. Lagrou,, J. Maertens, and, E. Van Wijngaerden. 2007. Invasive aspergillosis in the intensive care unit. Clin. Infect. Dis. 45: 205216.
37. Morrissey, C. O.,, M. A. Slavin,, M. A. O’Reilly,, J. Daffy, and, L. Coyle. 2004. Caspofungin (CAS) as salvage therapy (Rx) for invasive aspergillosis (IA): results of the Australian Compassionate Access Program (CAP), abstr. M-670. 44th Intersci. Conf. Antimicrob. Agents Chemother., 30 October to 2 November 2004. ASM, Washington, DC.
38. Pagano, L.,, M. Caira,, A. Nosari,, M. T. Van Lint,, A. Candoni,, M. Offidani,, T. Aloisi,, G. Irrera,, A. Bonini,, M. Picardi,, C. Caramatti,, R. Invernizzi,, D. Mattei,, L. Melillo,, C. de Waure,, G. Reddiconto,, L. Fianchi,, C. G. Valentini,, C. Girmenia,, G. Leone, and, F. Aversa. 2007. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin. Infect. Dis. 45:11611170.
39. Pagano, L.,, M. Caira,, A. Candoni,, M. Offidani,, L. Fianchi,, B. Mar-tino,, D. Pastore,, M. Picardi,, A. Bonini,, A. Chierichini,, R. Fanci,, C. Caramatti,, R. Invernizzi,, D. Mattei,, M. E. Mitra,, L. Melillo,, F. Aversa,, M. T. Van Lint,, P. Falcucci,, C. G. Valentini,, C. Girmenia, and, A. Nosari. 2006. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:10681075.
40. Pascual, A.,, T. Calandra,, S. Bolay,, T. Buclin,, J. Bille, and, O. Mar-chetti. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201211.
41. Petraitis, V.,, R. Petraitiene,, A. H. Groll,, A. Bell,, D. P. Callender,, T. Sein,, R. L. Schaufele,, C. L. McMillian,, J. Bacher, and, T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:28982905.
42. Pfaller, M. A.,, F. Marco,, S. A. Messer, and, R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251255.
43. Rocha, E. M.,, G. Garcia-Effron,, S. Park, and, D. S. Perlin. 2007. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51:41744176.
44. Sanz-Rodriguez, C.,, R. Martino, and, M. Canales. 2002. Caspofungin therapy in documented fungal infections in patients with hematological disorders: Spanish experience before licensure of the drug. Abstr. P-2483. Annu. Meet. Am. Soc. Hematol., 7 to 11 December 2002, Philadelphia, PA.
45. Sanz-Rodriguez, C.,, M. Lopez-Duarte,, M. Jurado,, J. Lopez,, R. Ar-ranz,, J. M. Cisneros,, M. L. Martino,, P. J. Garcia-Sanchez,, P. Morales,, T. Olivé,, M. Rovira, and, C. Solano. 2004. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant. 34: 1320.
46. Serrano, M.,, A. Valverde-Conde,, M. Chávez,, S. Bernal,, R. M. Clara,, J. Pemán,, M. Ramirez, and, E. MartÍn-Mazuelos. 2003. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn. Microbiol. Infect. Dis. 45: 131135.
47. Silveira, F. P., and, S. Husain. 2007. Fungal infections in solid organ transplantation. Med. Mycol. 45:305320.
48. Singh, N.,, A. P. Limaye,, G. Forrest,, N. Safdar,, P. Muñoz,, K. Pursell,, S. Houston,, F. Rosso,, J. G. Montoya,, P. Patton,, R. Del Busto,, J. M. Aguado,, R. A. Fisher,, G. B. Klintmalm,, R. Miller,, M. M. Wagener,, R. E. Lewis,, D. P. Kontoyiannis, and, S. Husain. 2006. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, mul-ticenter, observational study. Transplantation 81:320326.
49. Steinbach, W. J.,, D. A. Stevens, and, D. W. Denning. 2003. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37:(Suppl. 3):S188S224.
50. Stone, J. A.,, E. M. Migoya,, L. Hickey,, G. A. Winchell,, P. J. Deutsch,, K. Ghosh,, A. Freeman,, S. Bi,, R. Desai,, S. C. Dilzer,, K. C. Lasseter,, W. K. Kraft,, H. Greenberg, and, S. A. Waldman. 2004. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. 48:43064314.
51. Tawara, S.,, F. Ikeda,, K. Maki,, Y. Morishita,, K. Otomo,, N. Teratani,, T. Goto,, M. Tomishima,, H. Ohki,, A. Yamada,, K. Kawabata,, H. Takasugi,, K. Sakane,, H. Tanaka,, F. Matsumoto, and, S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44: 5762.
52. Traxler, P.,, W. Tosch, and, O. Zak. 1987. Papulacandins: synthesis and biological activity of papulacandin B derivatives. J. Antibiot. 40: 11461164.
53. Trenschel, R.,, M. Ditschkowski,, A. H. Elmaagacli,, M. Koldehoff,, H. Ottinger,, N. Steckel,, M. Hlinka,, R. Peceny,, P. M. Rath,, H. Der-moumi, and, D. W. Beelen. 2005. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant. 35: 583586.
54. Vazquez, J. A., and, J. D. Sobel. 2006. Anidulafungin: a novel echin-ocandin. Clin. Infect. Dis. 43: 215222.
55. Viscoli, C.,, R. Herbrecht,, H. Akan,, L. Baila,, C. Doyen,, A. Gallamini,, A. Giagounidis,, O. Marchetti,, R. Martino,, L. Meert,, M. Paesmans,, M. Shivaprakash,, A. J. Ullmann,, J. A. Maertens, et al. 2007. Cas-pofungin as first-line therapy of invasive aspergillosis in haemato-logical patients: a study of the EORTC infectious diseases group. Abstr. O-43. 3rd Trends Med. Mycol., 28 to 31 October 2007, Turin, Italy.
56. von Mach, M. A.,, J. Burhenne, and, L. S. Weilemann. 2006. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin. Pharmacol. 6:6.
57. Walsh, T. J.,, H. Teppler,, G. R. Donowitz,, J. A. Maertens,, L. R. Baden,, A. Dmoszynska,, O. A. Cornely,, M. R. Bourque,, R. J. Lupi-nacci,, C. A. Sable, and, B. E. dePauw. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351: 13911402.
58. Wingard, J. R. 2002. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin. Infect. Dis. 35: 891895.


Generic image for table
Table 1.

Comparison of echinocandins in adults

Citation: Maertens J, Maertens V. 2009. Echinocandins in the Treatment of Aspergillosis, p 435-443. In Latgé J, Steinbach W (ed), and Aspergillosis. ASM Press, Washington, DC. doi: 10.1128/9781555815523.ch32

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error